New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders

Musculoskeletal disorders such as rheumatoid arthritis (RA) and osteoarthritis are a common cause of pain and disability. The vasculature is an important component of the musculoskeletal system, and vascularization is a key event in the development of normal cartilage and bone. By promoting the deli...

Full description

Saved in:
Bibliographic Details
Published in:International journal of experimental pathology 1999-10, Vol.80 (5), p.235-250
Main Authors: Ballara, Sundeept C., Miotla, Jadwiga M., Paleolog, Ewa M.
Format: Article
Language:English
Subjects:
Angiogenesis
arthritis
Arthritis - physiopathology
Biological and medical sciences
Diseases of the osteoarticular system
Endothelial Growth Factors - physiology
Humans
Inflammatory joint diseases
Joints - blood supply
Lymphokines - physiology
Medical sciences
Musculoskeletal Diseases - drug therapy
Musculoskeletal Diseases - physiopathology
musculoskeletal disorders
Neovascularization, Pathologic - drug therapy
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
VEGF
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Musculoskeletal disorders such as rheumatoid arthritis (RA) and osteoarthritis are a common cause of pain and disability. The vasculature is an important component of the musculoskeletal system, and vascularization is a key event in the development of normal cartilage and bone. By promoting the delivery of nutrients, oxygen and cells, blood vessels help maintain the structural and functional integrity of joints and soft tissue and may facilitate tissue repair and healing. The identification of pro‐angiogenic mediators such as vascular endothelial growth factor (VEGF) has led to the development of antiangiogenic therapies for the treatment of neoplastic diseases. The important role of angiogenesis, and especially VEGF, in the pathogenesis of joint disorders such as RA suggests that antiangiogenic therapy may be a useful adjunct to existing approaches in RA.
ISSN:0959-9673
1365-2613
DOI:10.1046/j.1365-2613.1999.00129.x